Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04505293 · ClinicalTrials.gov registry record · NA

Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas

A NA study, sponsored by Duke University.

Completed
Registry status
NA
Development phase
672
Enrollment target

NCT04505293 is a NA study that has completed, run by Duke University. The registered enrollment target is 672 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04505293, a NA study, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
672 participants
Enrollment target

Study Summary

The goal of this study is to determine the sensitivity, specificity, and positive and negative predictive values of the a portable near-infrared-based device (portable NIR-based device), the InfraScanner 2000™, to detect intracranial hematomas (epidural hematomas (EDH) and/or subdural hematomas (SDH)) in patients hospitalized at Mbarara Regional Referral Hospital (MRRH) who have sustained or who are suspected to have sustained head trauma.

Interventions

  • DEVICE InfraScanner 2000™

Trial Details

FieldValue
Enrollment Target 672 participants
Start Date 2021-10-05
Est. Completion 2022-08-05
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT04505293

The ClinicalTrials.gov registry entry for NCT04505293 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 672 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which InfraScanner 2000™ is the first listed.

NCT04505293 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04505293 about?

NCT04505293 is a clinical study titled "Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas". The goal of this study is to determine the sensitivity, specificity, and positive and negative predictive values of the a portable near-infrared-based device (portable NIR-based device), the InfraScanner 2000™, to detect intracranial hematomas (epidural hematomas (EDH) and/or subdural hematomas (SDH...

What is the current status of trial NCT04505293?

This trial is currently completed. It is a NA study. The enrollment target is 672 participants. The study started on 2021-10-05. Estimated completion is 2022-08-05.

What interventions are being tested in trial NCT04505293?

The interventions under investigation include: InfraScanner 2000™ (DEVICE).

Who is sponsoring clinical trial NCT04505293?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.